Liu Xiaoxiao, Yuan Ling, Chen Fang, Zhang Lizhu, Chen Xi, Yang Chengjian, Han Zhijun
Clin Lab. 2017 Jan 1;63(1):101-109. doi: 10.7754/Clin.Lab.2016.160632.
MicroRNAs are present in human plasma and have been reported to be biomarkers for cardiovascular diseases. The aim of this study was to investigate the value of circulating microRNA-208b (miR-208b) for the diagnosis and prognosis of acute myocardial infarction (AMI).
A total of 100 AMI patients, 80 unstable angina (UA) patients, and 80 healthy controls (HCs) were consecutively included in this study. Plasma was collected from each participant on admission, and the levels of circulating miR-208b were measured using reverse transcription-polymerase chain reaction (RT-PCR). The AMI patients who underwent percutaneous coronary intervention (PCI) were followed up at 6 months post-AMI.
The concentration of miR-208b was higher in the AMI patients than in the other two groups (p < 0.05), and it was positively correlated with the levels of creatine kinase (CK)-MB and cardiac troponin I (cTnI) (p < 0.01). Moreover, the receiver operating characteristic (ROC) curves showed that miR-208b was sensitive like CK-MB and cTnI for the diagnosis of AMI. In addition, the miR-208b concentration in AMI patients with threevessel coronary artery disease (CAD) was higher than that of single- or two-vessel CAD AMI patients (p < 0.05). Also, the miR-208b expression after PCI was significantly lower than on admission (p < 0.01). Furthermore, miR208b expression in AMI patients with left ventricular remodeling/MACEs was higher than in those without after PCI (p < 0.05).
Circulating miR-208b may serve as a sensitive biomarker for the diagnosis and prognosis of AMI patients.
微小RNA存在于人体血浆中，据报道可作为心血管疾病的生物标志物。本研究旨在探讨循环微小RNA-208b（miR-208b）对急性心肌梗死（AMI）诊断和预后的价值。
本研究连续纳入了100例AMI患者、80例不稳定型心绞痛（UA）患者和80例健康对照者（HCs）。在入院时采集每位参与者的血浆，使用逆转录-聚合酶链反应（RT-PCR）检测循环miR-208b的水平。对接受经皮冠状动脉介入治疗（PCI）的AMI患者在AMI后6个月进行随访。
AMI患者中miR-208b的浓度高于其他两组（p<0.05），且与肌酸激酶（CK）-MB和心肌肌钙蛋白I（cTnI）水平呈正相关（p<0.01）。此外，受试者工作特征（ROC）曲线显示，miR-208b在诊断AMI方面与CK-MB和cTnI一样敏感。另外，三支冠状动脉疾病（CAD）的AMI患者中miR-208b浓度高于单支或双支CAD的AMI患者（p<0.05）。而且，PCI后miR-208b的表达明显低于入院时（p<0.01）。此外，PCI后发生左心室重构/主要不良心血管事件（MACEs）的AMI患者中miR-208b的表达高于未发生者（p<0.05）。
循环miR-208b可能作为AMI患者诊断和预后的敏感生物标志物。
